Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors
in Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 130-136, 2022.
Artigo
em Chinês
| WPRIM
| ID: wpr-928790
ABSTRACT
Surgery is the standard treatment for resectable non-small cell lung cancer (NSCLC). Neoadjuvant and adjuvant therapy have been widely used for preventing recurrence and metastasis. Immune checkpoint inhibitors (ICIs) have brought long-term survival benefits in advanced NSCLC and showed higher downstage rates and pathological remission in the neoadjuvant setting. Predictive biomarkers are of great significance to identify the beneficiaries of neoadjuvant ICIs. At present, the biomarkers are still inconclusive. We summarized the clinical trials of neoadjuvant immune checkpoint inhibitors that have been disclosed so far, and reviewed the progress of the biomarkers associated with those trials.
.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Biomarcadores
/
Carcinoma Pulmonar de Células não Pequenas
/
Terapia Neoadjuvante
/
Inibidores de Checkpoint Imunológico
/
Neoplasias Pulmonares
Tipo de estudo:
Estudo prognóstico
Limite:
Humanos
Idioma:
Chinês
Revista:
Chinese Journal of Lung Cancer
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS